Program Committee
Share |
Chair: Marie-Francoise Chesselet, MD, PhD
Co-chair: Peter Fletcher, MB.ChB, MSc
Co-chair: Peter LeWitt, MD

Program Subcommittees:

Basic Science Subcommittee
Chair: Marie-Francoise Chesselet, MD, PhD (USA)

Anders Bjorklund, MD, PhD (Sweden)
Patrik Brundin, MD, PhD (USA)
Nicole Calakos, PhD (USA)
Jeff Conn, PhD (USA)
Ted Dawson, PhD (USA)
Thomas Gasser, PhD (Germany)
Glenda Halliday, PhD (Australia)
Etienne Hirsch, PhD (France)
Ryuji Kaji, MD, PhD (Japan)
Un Kang, MD (USA)
Heidi McBride, PhD (Canada)
Jon Palfreman, PhD (USA)
Jon Stamford, PhD (UK)
David Standaert, MD, PhD (USA)
Malu Tansey, PhD (USA)
George Veomett, PhD (USA)

Clinical Science Subcommittee
Co-Chair: Peter LeWitt, MD (USA)

Angelo Antonini, PhD (Italy)
Roongroj Bhidayasiri, MD, FRCP, FRCPI (Thailand)
Michael Okun, MD (USA)
Francisco Cardoso, MD, PhD (Brazil)
Susan Fox, MD, PhD (Canada)
Tom Isaacs (UK)
Alberto Espay, MD (USA)
K. Ray Chaudhuri, DSc, FRCP, MD (UK)
Simon Lewis, MD, MBBCH (Australia)
Tim Hague, RN (Canada)
Shen-Yang Lim, MD (Malaysia)
Irene Litvan, MD (USA)
Jose Obeso, MD (Spain)
Barry Snow, MD (New Zealand)
Caroline Tanner, PhD (USA)
Eduardo Tolosa, MD (Spain)
Dan Weintraub, MD (USA)

Comprehensive Care Subcommittee
Co-Chair: Peter Fletcher, MSc, FRCP (UK)

Bastiaan Bloem, MD, PhD (Netherlands)
Elaine Book, SW (Canada)
Terry Ellis, PT, PhD (USA)
Joe Friedman, MD (USA)
Nir Giladi, MD (Israel)
Tom Isaacs (UK)
Lucie Lachance, RN (Canada)
Anne-Louse Lafontaine, MD (Canada)
Soania Mathur, MD (Canada)
Rebecca Miller, PhD (USA)
Ronald Pfeiffer, MD (USA)
Lynn Rochester, PhD (UK)

Marie-Francoise Chesselet, MD, PhD (USA) is the Charles H. Markham Professor of Neurology and distinguished Professor in the Department of Neurology and the Department of Neurobiology at UCLA. After receiving her M.D. and Ph.D. degrees in Paris, France, she held research positions in France and faculty positions at the Medical College of Pennsylvania and the University of Pennsylvania, before joining UCLA in 1996. At UCLA, Chesselet chaired the Department of Neurobiology from 2002 to 2013 and is currently the Director of the Integrative Center for Neural Repair, which includes the Center for the Study of Parkinson’s Disease at UCLA she created in 1998. She has directed the NIH-funded UCLA UDALL Center for Parkinson’s disease research (NINDS; 1998-2013) and UCLA Center for Gene Environment in Parkinson’s Disease (NIEHS; 2002-2014), and the UCLA Advanced Center for Parkinson’s Disease Research of the American Parkinson Disease Association since 1998. Chesselet has directed graduate programs at the University of Pennsylvania and UCLA and has directed the NINDS-funded Training Program in Neural Repair since 1998. Her laboratory conducts research on the molecular mechanisms of disorders of the basal ganglia and new treatments for Parkinson’s and Huntington’s diseases. Currently, her work is supported by, the Department of Defense, the Michael J. Fox Foundation, CIRM, and biopharmaceutical companies. Chesselet is a Fellow of the American Association for the Advancement of Science and the Chair-elect of its section on Neuroscience. She serves on the National Advisory Environmental Health Sciences Council (NIEHS Council).

Anders Bjorklund, MD, PhD (Sweden) has been researching reparative and neuroprotective mechanisms in the CNS using cell replacement and gene transfer techniques. In the 1970s his group pioneered studies of neural transplantation to the brain, and developed techniques for cell replacement in animal models of Parkinson's disease. Over the last 15 years the Lund neural transplantation program, headed by Professor Olle Lindvall, has been one of the leading clinical programs for the development of restorative therapies in Parkinson's disease.

Current research at the Wallenberg Neuroscience Center is focused on the use of neural stem cells and viral vector-mediated gene transfer for neuroprotection and brain repair, with the aim to develop new therapeutic approaches for Parkinson's disease and other neurodegenerative disorders.

Patrik Brundin, MD, PhD (USA) has more than 30 years of experience studying neurodegenerative diseases, Parkinson's disease pathogenesis and therapeutic neural grafting into people with Parkinson's disease. He is one of the top cited researchers in the field of neuroscience with nearly 300 publications on Parkinson's disease and related topics. In addition to managing his laboratory at Van Andel Research Institute, he is the co-editor in chief of the Journal of Parkinson's Disease, the chair of the Linked Clinical Trials committee, and has coordinated multiple international research programs. Dr. Brundin is the Associate Director of Research at Van Andel Research Institute, Director of Van Andel Research Institute’s Center for Neurodegenerative Science, head of the Laboratory for Translational Parkinson’s Disease Research and the Jay Van Andel Endowed Chair in Parkinson’s Research.

Nicole Calakos, PhD (USA)

Jeff Conn, PhD (USA) is the Lee E. Limbird Professor of Pharmacology at Vanderbilt University and Director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD). Dr. Conn received a Ph.D. in Pharmacology from Vanderbilt in 1986 and pursued postdoctoral studies at Yale University. Dr. Conn joined the faculty of the Department of Pharmacology at Emory University in 1988 where he where he established himself as a leader in studies of neurotransmitter receptors and their roles in regulating brain function in circuits involved in psychiatric and neurological disorders. In 2000, Dr. Conn assumed the position of Senior Director and Head of the Department of Neuroscience at Merck and Company in West Point, PA. In addition to directing the drug discovery efforts of his department in multiple CNS therapeutic areas, Dr. Conn was responsible for overseeing the global efforts of the company in discovery of new therapeutic agents for treatment of schizophrenia and movement disorders.

Dr. Conn moved to Vanderbilt University in 2003 where he is the founding director of the VCNDD, with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics. By 2011 the VCNDD had grown to approximately 100 full time scientists and under his leadership raised over $100M in external research funding. In addition, the VCNDD advanced novel molecules from multiple major programs into development for major brain disorders with industry partners, including Johnson and Johnson, Astrazeneca, Bristol Myers Squibb, and others. Each of these major efforts are focused on novel mechanisms for therapeutic action that have come from the basic research efforts of Dr. Conn and his collaborators. Dr. Conn has served as Associate Editor and Editor in Chief of Molecular Pharmacology and in editorial positions with multiple other international journals. He has served the Scientific Advisory Boards of multiple foundations, research institutes, and companies. He served as Chairman of the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics (ASPET), Fellow of the American Association for the Advancement of Science, and on multiple national and international committees. He has received numerous awards, including the NARSAD Essel Distinguished Investigator Award, the ASPET-Astellas Award in Translational Pharmacology, the Pharmacia - ASPET Award for Experimental Therapeutics, the Charles R. Park Award for Basic Research Revealing Insights into Physiology and Pathophysiology, the PhRMA Foundation Award for Excellence in Pharmacology and Toxicology. V. Sagar Sethi Mental Health Research Award, Jacob K. Javits Neuroscience Investigator Award from the National Institute of Neurological Disorders & Stroke. He was named as an ISI Most- Cited Scientists in Pharmacology & Toxicology and the Lee University 2008 Distinguished Alumnus of the Year. Dr. Conn’s current research is focused on development of novel treatment strategies for schizophrenia, Parkinson’s disease, and other serious brain disorders.

Ted Dawson, PhD (USA) is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases in the Departments of Neurology and Neuroscience and the Graduate Program in Cellular & Molecular and the Institute for Cell Engineering at the Johns Hopkins University School of Medicine. He is the Scientific Director of the Institute for Cell Engineering and he is the Director of the Johns Hopkins University School of Medicine's Morris K. Udall Parkinson's Disease Research Center of Excellence. Dr. Dawson is world-renowned for his novel contributions on the role of nitric oxide in neuronal injury. He has published over 400 full-length manuscripts and review articles. He is one of the top five cited Neuroscientists in the last decade. Dr. Dawson has won several awards including the Derek Denny-Brown Young Neurological Scholar Award, the Paul Beeson Physician Faculty Scholar Award, the Santiago Grisolia Medal and the ISI Highly Cited Researcher Award. He was elected to the Association of American Physicians and he is a Fellow of the American Association for the Advancement of Science. He is the Chairman of Scientific Advisory Board of the Bachman-Strauss Dystonia and Parkinson Foundation and serves on the Medical Advisory Board of the Society for Progressive Supranuclear Palsy and he is a member of the Faculty of 1000 Biology Neurobiology of Disease and Regeneration Section of the Neuroscience Faculty. Many advances in neurobiology of disease have stemmed from Dr. Dawson's identification of the mechanisms of neuronal cell death and the elucidation of the molecular mechanisms of neurodegeneration. He pioneered the role of nitric oxide in neuronal injury in stroke and excitotoxicity and elucidated the molecular mechanisms by which nitric oxide and poly (ADP-ribose) polymerase and apoptosis inducing factor kills neurons. His studies of nitric oxide led to major insights into the neurotransmitter functions of this gaseous messenger molecule. He discovered the neurotrophic properties of non-immunosuppressant immunophilin ligands. Dr. Dawson has been at the forefront of research into the biology and pathobiology of the proteins and mutant proteins linked to Parkinson's disease. These studies are providing major insights into understanding the pathogenesis of PD and are providing novel opportunities for therapies aimed at preventing the degenerative process of PD and other neurodegenerative disorders.

Thomas Gasser, PhD (Germany) is Professor of Neurology at the University of Tübingen, Director of the Department of Neurodegenerative Diseases at the Hertie-Institute for Clinical Brain Research and Chairman of the German Center of Neurodegenerative Diseases in Tübingen.

Prof. Gasser studied medicine at the University of Freiburg, Germany, and at Yale University Medical School, New Haven Connecticut . He received his professional training in psychiatry at the Max Planck-Institute of Psychiatry in Munich and in Neurology at the Department of Neurology of the Ludwig-Maximilians University in Munich . From 1991 to 1993 he trained as a post-doctoral fellow with a stipend of the German Research Foundation at the Neuroscience Center, Massachusetts General Hospital and Harvard Medical School, in Boston in the laboratory of Prof. Xandra Breakefield. He returned to Munich to become assistant professor in Neurology and head of the Neurogenetics Unit as well as the Movement Disorders Outpatient Unit at the Department of Neurology of Munich University . In 2002, he became head of the Department of Neurodegenerative Diseases of the Hertie-Institute of Clinical Brain Research and in 2009 chairman of the German Center for Neurodegenerative Diseases in Tübingen.

His main areas of research are the genetic and molecular basis of Parkinson's disease, dystonia and other movement disorders, as well as their diagnosis and treatment.

Glenda Halliday, PhD (Australia) received her degrees from the University of New South Wales and her postdoctoral training in South Australia prior to returning to Sydney as an Australian Research Council Queen Elizabeth II Fellow. She has been a research fellow of the National Health and Medical Research Council of Australia since then and a senior scientist at Neuroscience Research Australia (joined in 1993). Her expertise is in the pathogenesis of neurodegenerative disorders, having published over 300 research publications and two books, the most recent on Parkinson’s disease. She was president of the Australian Neuroscience Society from 2006-2007. Her research has highlighted broader pathological involvement in Parkinson's disease and in dementia with Lewy bodies, initially finding that more than the dopamine system was damaged, and then that Lewy bodies associated with visual hallucinations rather than a loss of function. Her current work focuses on how proteins identified through genetic studies are involved in neurodegeneration.

Etienne Hirsch, PhD (France) is a neurobiologist involved in research on Parkinson’s disease and related disorders. He obtained his PhD in 1988 from the University of Paris VI (Pierre et Marie Curie). He is currently the associate director of CRICM and head of "Experimental therapeutics of Neurodegeneration” at the CRICM at Pitié-Salpêtrière hospital in Paris and councilor for Neuroscience, Neurology and Psychiatry at the French Ministry for higher education and research. He has also been appointed director of the national Institute (ITMO) for neurosciences, cognitive sciences, neurology and psychiatry. His work is aimed at understanding the cause of neuronal degeneration in Parkinson’s disease and is focused on the role of the glial cells, the inflammatory cytokines and apoptosis but also on the consequences of neuronal degeneration in the circuitries downstream to the lesions. He is member of several advisory boards including, French Society for Neuroscience (past-President), Scientific Advisory board at INSERM. He obtained several prizes including Tourette Syndrome Association Award in1986, Young researcher Award, European Society for Neurochemistry in 1990, Grand Prix de l’Académie de Sciences, Prix de la Fondation pour la recherche biomédicale « Prix François Lhermitte » in 1999, Chevalier de l’ordre des palmes académiques in 2009, Prix Raymond et Aimée Mande of the French National academy of Medicine in 2011, Member of the French National Academy of Pharmacy in 2011. He is author of more than 200 peer reviewed articles.

Ryuji Kaji, MD, PhD (Japan) is Professor and Chairman of the Department of Neurology at Tokushima University , Graduate School of Medicine, Tokushima, Japan . H e has been a member of The Movement Disorder Society (MDS) since 199 1 and has served on the MDS Membership and Congress Scientific Program Committee s, as well as on the Editorial Board of Movement Disorders journal.

Dr. Kaji received neurology and neurophysiology training at the University of Pennsylvania and completed a movement disorders training course at the Kyoto University Hospital. His research interests have been focused on the study of pathophysiology, molecular genetics, and functional neuroanatomy of dystonia, especially those of lubag dystonia.

Un Kang, MD (USA) received his medical degree from the Johns Hopkins University and obtained his neurology residency and movement disorders fellowship training at Columbia University. He worked at the University of Chicago from 1992 to 2013 and moved back to Columbia in 2013.

His clinical expertise is in movement disorders including Parkinson’s disease (PD). Dr. Kang's research interests include understanding the mechanisms of both beneficial and detrimental effects of dopaminergic therapy such as dyskinesia. He is also interested in understanding the mechanisms of neurodegeneration by studying the genes associated with PD.

Heidi McBride, PhD (Canada) is a graduate of McGill (B.Sc ’91, Ph.D ’96) and completed her post-doctoral training at the EMBL in Heidelberg, Germany in 2000. She spent her years as a trainee in the fields of mitochondrial protein import and the molecular mechanisms of endocytosis, Rab activation and SNARE assembly. Within her own lab over the past decade, she has made numerous discoveries into the fundamental behaviour of the mitochondria and how they are integrated into the cellular environment. After 11 years at the University of Ottawa Heart Institute, she relocated her lab to McGill University (June 2011). As an Associate Professor in the Department of Neurology and Neurosurgery, she is engaged in training undergraduates, grad students and post-doctoral fellows. With a highly collaborative spirit, she joined the Neuromuscular Group at the Montreal Neurological Institute where she will help to create a dynamic, multidisciplinary team to tackle the complex problems of neurodegenerative diseases like ALS, Parkinsons, Huntingtons and various forms of Ataxias.

Jon Palfreman, PhD (USA) is KEZI Distinguished Professor of Broadcast Journalism at the University of Oregon, USA. Palfreman, the author of BRAIN STORMS: The Race to Unlock the Mysteries of Parkinson’s Disease, (due out in September 2015) is an Emmy, Dupont and Peabody Award-winning journalist, and recipient of the Victor Cohn Prize for Excellence in Medical Writing. He is a three-time winner of the American Association for the Advancement of Science science-writing prize, three-time winner of the National Association of Science Writers "Science-in-Society" Journalism Award and a winner of the Writers Guild Award for best script. In the area of Parkinson's Disease research, Palfreman previously co-authored a book with neuroscientist Bill Langston (LPD co-Editor-in-Chief), The Case of the Frozen Addicts, and produced two NOVA documentaries chronicling the story of the MPTP cases, NOVA: The Case of the Frozen Addict and NOVA: Brain Transplant. He was recently made Social Media Editor of the Journal of Parkinson's Disease. Palfreman was a 2006 Nieman Fellow in Journalism at Harvard University.

Jon Stamford, PhD (UK) is a neuroscientist with a double interest in Parkinson's. As well as leading a research laboratory investigating the neurochemistry of Parkinson's for more than a decade, Dr. Stamford also has young onset Parkinson's disease. He has published three neuroscience books and more than 200 research publications (reviews, papers, abstracts) in an academic career lasting 23 years.He holds an honorary readership at the University of Leicester, andis a scientific consultantand member of the patient advocates groupwith the Cure Parkinson's Trust.Jon also writes a humorous and influentialweekly blog "Slice of Life"about life with young onset Parkinson's

David Standaert, MD, PhD (USA) graduated from Harvard College in 1982. He received his M.D. and Ph.D. degrees from Washington University in St. Louis. He completed a one-year internship in Medicine followed by a three-year Neurology residency at the University of Pennsylvania. He was appointed a Howard Hughes Medical Institute Physician Research Fellow, and completed a three-year research and clinical fellowship in Neurology (Movement Disorders) at Massachusetts General Hospital in 1995. He subsequently joined the faculty at Harvard Medical School and MGH, where he served as Director of the MGH/MIT Udall Center of Excellence in PD Research. Dr. Standaert relocated to the University of Alabama at Birmingham in July of 2006 and is now the John N. Whitaker Professor and Chair of the Department of Neurology. He serves as Director of the Division of Movement Disorders, the Director of the APDA Advanced Center for Parkinson Research at UAB, and is the Director of the Center for Neurodegeneration and Experimental Therapeutics. He sees patients in a weekly clinic and oversees many clinical trials for new treatments of Parkinson's disease. He is a member of the Scientific Advisory Boards of the Michael J. Fox Foundation for Parkinson Research, the American Parkinson Disease Association, and the Bachmann-Strauss Dystonia & Parkinson Foundation. Dr. Standaert’s laboratory works on understanding both the root causes of Parkinson’s disease as well as the origin of the disabling symptoms that appear after long term treatment of the disease. Recently, his group has focused on approaches to reducing the toxicity of synuclein in animal models of Parkinson disease, and the role of neuroinflammatory reactions in disease progression.

Malu Tansey, PhD (USA) obtained her BS/M in biological sciences from Stanford University and her PhD in physiology from The University of Texas Southwestern Graduate School of Biomedical Sciences in Dallas, Texas. During her postdoc training at Washington University Medical School in the laboratory of Eugene M. Johnson Jr., she and her colleagues identified and characterized new members of the GDNF family of ligands (GFLs: Neurturin, Persephin, and Artemin). As group leader of chemical genetics at Xencor Inc., she and her colleagues developed a new class of TNF inhibitors using a proprietary protein engineering platform. In 2002, she set up her own research program at UT Southwestern to investigate the role of TNF signaling in the CNS and its impact on neuronal survival with the long-term goal of developing new therapies for neurodegenerative diseases. She is now a tenured associate professor of physiology and member of the Center for Neurodegenerative Diseases at Emory University School of Medicine in Atlanta, Georgia. Research in her lab is aimed at understanding mechanisms underlying CNS-immune system cross-talk in health and disease.

George Veomette, PhD (USA) was born and raised in Rochester NY, receiving a Bachelor’s degree in biology from the University of Rochester (1966), he received his Ph.D from the University of Colorado (1972), doing both graduate and post-graduate work in the Dept of Molecular, Cellular and Developmental Biology.  Most of George's professional life was spent at the University of Nebraska-Lincoln in the School of Biological Sciences. He taught primarily developmental and cellular biology and conducted research on cellular growth factors. He served in several different administrative capacities, from Vice Director of the School of Biological Sciences to being President of the Nebraska Academy of Sciences. George has also been the fellow traveler of Marilyn in her and their life with Parkinson’s Disease for more than 15 years. Through the years they have attended numerous conferences, workshops, and special presentations, they have been a part of and have led support groups, and we have been the scientific liaisons for a local PD funding group. George and Marilyn especially enjoyed and appreciated the 3rd WPC and are honored to work for the 4th.

Peter LeWitt, MD (USA) who directs the Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital in West Bloomfield, was appointed Professor of Neurology at Wayne State University School of Medicine in 1990. A graduate of Brown University School of Medicine (and also awarded a M.Med.Sc. in Biochemical Pharmacology), his neurology residency training was at Stanford University School of Medicine. His completed fellowship training in experimental therapeutics at the National Institute of Neurological and Communicative Disorders. In addition to conducting clinical trials for Parkinson’s disease and other neurological disorders, his research interests have also included animal models and biomarkers of neurological disease, pharmacokinetic analysis, and gene therapy for Parkinson’s disease. He is the author of more than 300 publications in basic and clinical neuroscience.

Dr. LeWitt was a founding member of the Parkinson Study Group and was elected in 1998 to serve as secretary of the Movement Disorder Society. He is a member of that organization’s Task Force for the Development of Rating Scales for Parkinson’s Disease. Dr. LeWitt has been a recipient or reviewer of research grants from the National Institutes of Health, the Michael J. Fox Foundation for Parkinson’s Research, the National Parkinson Foundation, the U.S.-Israel Bi-National Science Foundation, and other organizations. Since 2003, he has been editor-in-chief of Clinical Neuropharmacology and has served on the editorial boards of Movement Disorders, Journal of Neural Transmission, Journal of Parkinson’s Disease, and Translational Neurodegeneration. Dr. LeWitt has been the mentor for several movement disorder fellowship trainees and has been active in educational programs conducted by the Movement Disorder Society, the American Academy of Neurology, the European Federation of Neurological Sciences, and other organizations.

Angelo Antonini, PhD (Italy) is Professor of Neurology and director of the Parkinson Department at the Institute of Neurology, IRCCS San Camillo in Venice.

He earned his medical degree from the Università degli Studi di Roma ‘La Sapienza’, Rome. In November 1990 he completed his neurology training with honors and then undertook a visiting fellowship at the PET Department Paul Scherrer Institute, Villigen, Switzerland before starting his PhD in neuroradiology under the supervision of Professor Klaus Leenders. In 1995 he received the first award from the National Parkinson Foundation for ‘young researchers in Parkinson’s disease’. In 1996 he was awarded the Junior Faculty Award 1996/97 from United Parkinson Foundation and Parkinson's Disease Foundation for his research in the field of Parkinson’s disease. From November 1997 to end 2009 he worked at the Parkinson Institute in Milan where he coordinated Clinical Research at the Department of Neuroscience.

His research focuses on pharmacology of dopaminergic medications, neuroimaging as well as cognitive and behavioral aspects of Parkinson’s disease. In addition he is actively involved in the use of continuous infusion of levodopa and apomorphine as well as subthalamic nucleus deep brain stimulus (STN-DBS) for the treatment of motor fluctuations and dyskinesia of complicated Parkinson patients.

During his academic career he has published almost 200 peer-reviewed manuscripts and several book chapters. He serves as reviewer for the main neurology journals and has served on the editorial board of Movement Disorders as well in several committees of the Movement Disorders Society. He is also treasurer of the Association of Parkinsonism and Related Disorders.

Roongroj Bhidayasiri, MD, FRCP, FRCPI (Thailand)

Michael Okun, MD (USA) is the Adelaide Lackner Professor of Neurology at the University of Florida, and the Administrative Director and co-founder of the UF Center for Movement Disorders and Neurorestoration. Dr. Okun completed his M.D. degree and his neurology residency training at the University of Florida where he graduated with Honors. He completed his fellowship training in movement disorders at Emory University. Currently the center he directs has 45 interdisciplinary faculty members dedicated to care, outreach, education and research for Parkinson’s disease and movement disorders. He serves as the National Medical Director for the National Parkinson Foundation and administrates the NPF Ask the Expert web-forums. He co-chairs the Medical Advisory Board for the Tourette Syndrome Association. Dr. Okun’s research has explored motor and non-motor basal ganglia brain disorders and deep brain stimulation. He has published over 250 peer-reviewed papers exploring cognitive, behavioral, and mood effects of basal ganglia disorders. His newest book on Parkinson's disease has been translated into over 20 languages- Parkinson's Treatment: 10 Secrets to a Happier Life.

Francisco Cardoso, MD, PhD (Brazil)

Susan Fox, MD, PhD (Canada) is Associate Professor Neurology, University of Toronto and Staff Neurologist Movement Disorders Clinic, Toronto Western Hospital, UHN, Canada. She performed her medical and neurological training in Manchester and Liverpool, UK. Appointed Consultant Neurologist, Walton Centre Liverpool 2001-2003. Moved to Canada in 2003 to take up current position. Research interests include preclinical studies of Parkinson’s disease investigating disease mechanisms, particularly neuropsychiatric problems as well as phase II and phase III clinical trials of new treatments for movement disorders. Currently also chair of the Movement Disorder society evidence based medicine update on treatment of motor symptoms for Parkinson’s disease.

Alberto Espay, MD (USA) trained in clinical and electrophysiology of Movement Disorders at the Toronto Western Hospital, completing an MSc program in Clinical Epidemiology and Health Care Research and a Dystonia Medical Research Foundation Clinical Research Fellowship (University of Toronto, 2001-2005). He has published over 60 peer-reviewed articles and book chapters, and has authored the books Concise Neurology (Lippincott Williams & Wilkins/Wolters Kluwer Health, 2011), with Dr. Jose Biller; Common Movement Disorders Pitfalls (Cambridge University Press, 2012), with Dr. Anthony Lang; and Practical Neurology Visual Review (Lippincott Williams & Wilkins/Wolters Kluwer Health, 2013 [in press]), with Dr. Jose Biller.

Dr. Espay received the Dean’s Scholar in Clinical Research Award by the University of Cincinnati for three consecutive years (2006-09), the NIH-funded KL2 Research Scholars Mentored Award (2010-12), and the NIH-funded K23 Career Development Award (2011-16). He is Associate Professor and Clinical Research Director of the James J. and Joan A. Gardner Center for Parkinson’s Disease and Movement Disorders at the University of Cincinnati, and has served as the neuroscience representative to the Institutional Review Board and the Advisory Board of UC Physicians Clinical Trials Organization. He serves as Assistant Editor of Movement Disorders, the official journal of the Movement Disorder Society, Associate Editor of Frontiers in Movement Disorders, and on the Editorial Board of The European Neurological Journal, as well as ad hoc reviewer for over 20 other neurological and medical journals. He has served as faculty for a variety of annual educational courses at the American Academy of Neurology and Movement Disorders Congresses since 2007. He became honorary member of the Mexican Academy of Neurology in 2008, joined the Best Doctors in America list in 2009, received the Business Courier’s 'Forty Under 40' award in 2010, and the Patients' Choice and Compassionate Doctor awards in 2011.

K. Ray Chaudhuri, DSc, FRCP, MD (UK) is a Professor in Neurology/Movement Disorders and Consultant Neurologist and at Kings College and Institute of Psychiatry, London an Academic Health Sciences Centre and also principal investigator at the MRC centre for neurodegeneration research at Kings College, London. He is the medical director of the National Parkinson Foundation International Centre of Excellence at Kings College, London. He sits on the Nervous Systems Committee of UK Department of Health, National Institute of Health Research and also serves as co-chairman of the appointments/liaison committee of the Movement Disorders Society and is currently serving as the member of the scientific programme committee of the MDS. He serves on the task force of practice parameter group for PD and RLS and more recently Non Motor Symptoms of Parkinson's, American Academy Neurology. He is the European Editor of Basal Ganglia and is in the editorial board of Parkinsonism and Related Disorders and Journal of Parkinson's Disease. He is also the lead for London South CLRN neurosciences sub-specialty group. He is the current Chairman of the Parkinson’s non-motor study group of the MDS.

Professor Ray Chaudhuri is the author of 215 papers including reviews, book chapters, co-editor of 4 books on Parkinson's disease and Restless Legs Syndrome and over 200 published peer reviewed abstracts. He is the chief editor of the first comprehensive textbook on non motor aspects of Parkinson’s, published by Oxford University Press and recipient of BMA book prize commendation prize. He has contributed extensively to educational radio and television interviews including BBC and CNN, newspaper articles and videos. He has also lectured extensively on PD and restless legs syndrome at international meetings in USA, Japan, continental Europe, South America, South Africa, India and Australia. His major research interests are continuous drug delivery treatment of PD and restless legs syndrome, Parkinsonism in minority ethnic groups and sleep problems in PD. In 2005 the University of London awarded him the DSc degree.

Simon Lewis, MD, MBBCH (Australia) is a Consultant Neurologist at the Royal Prince Alfred Hospital and Associate Professor in Cognitive Neuroscience at the University of Sydney. He has a specialist interest in both newly diagnosed and advanced Parkinson's Disease with expertise in freezing of gait, hallucinations, memory problems and sleep disturbances.

He undertook his Neurology training in Cambridge and London before moving to Sydney in 2007.

Tim Hague, RN (Canada) Winner of The Amazing Race Canada & Parkinson's Activist. Tim overcame the odds when he went from a diagnosis of Parkinson’s disease to—just three years later—becoming the inaugural winner of CTV’s The Amazing Race Canada. Tim’s message of strength and courage leaves audiences motivated to meet life’s challenges and do more than they ever thought they could.

Tim and his son, Tim Hague Jr., put their now-trademark perseverance to work while participating as a duo on The Amazing Race Canada. When the pair finally came out on top in the last competition of the race, they had never before won any stages and in fact had nearly been eliminated from the show twice. Despite the odds, “The Tims” as viewers affectionately dubbed them, kept their focus on overcoming one obstacle at a time to take the championship, a message of hope that Tim draws on in his talks.

As a Registered Nurse and Professional Speaker, Tim is active in the promotion of healthy, balanced lifestyles, and deeply involved in the promotion of Parkinson’s issues and building awareness around Young Onset Parkinson’s Disease working closely with groups such as the Parkinson Society and the Reh-Fit Centre.

Shen-Yang Lim, MD (Malaysia)

Irene Litvan, MD (USA) is the Tasch Endowed Chair of Parkinson Disease Research at the University of California San Diego (UCSD), Professor of Neurosciences and Director of the UCSD Movement Disorder Center. She has published more than 230 peer-reviewed articles and chapters on the diagnosis of neurodegenerative parkinsonian and dementia disorders and its neuropsychiatric aspects. She was editor/senior editor of 4 books on atypical parkinsonian disorders and dementias including the first one solely dedicated to progressive supranuclear palsy and first one on corticobasal degeneration. Dr. Litvan is a reviewer for several medical, neurologic and neuropsychologic journals. She mentors master, PhD candidates, medical students, residents and fellows. Dr. Litvan is a fellow of the American Neurological Association and of the American Academy of Neurology. She serves and has served on many boards and committees. She is currently the chair of the MDS Pan American Section Education Committee, secretary of the World Federation of Neurology Research Group on Dementia and member of the medical scientific boards of CurePSP, PSP Europe Association and the Association for Frontotemporal Dementias. She received the National Institutes of Health merit award for leading international multicenter studies to evaluate and improve the clinical diagnostic criteria of several dementia and parkinsonian neurodegenerative disorders. She is the principal investigator of a National Institutes of Aging multisite and multidisciplinary study to identify the genetic and environmental risk factors for progressive supranuclear palsy. The scope of her research is translational in its nature.

Jose Obeso, MD (Spain) is Full Professor and Consultant of Neurology in the School of Medicine and the University Hospital (Clínica Universitaria), and Senior Investigator in the Center for Applied Medical Research, University of Navarra, Pamplona, Spain.España. He graduated from the University of Navarra in 1976 and specialized in neurology and neurophysiology in San Sebastian and Pamplona, Spain. From 1980 to 1982 he worked as a researcher in movement disorders under the supervision of Professor C. David Marsden in London (UK), which proved to be the most exciting and decisive period in his career. In the University of Navarra, in Pamplona, and for a short period of time in Tenerife (Spain), Dr. Obeso has devoted his efforts to the care of patients with movement disorders, particularly Parkinson’s disease, and to clinical and laboratory research. Together with Tom Chase and Fabriccio Stochi, he pioneered the concept of "Continual Dopaminergic Stimulation” for treating Parkinson’s disease, and has played a major role in the recent renewal of interest in surgical treatment for Parkinson’s disease. He has published over 300 original research papers and 90 review articles, has edited 18 books and special issues of medical journals, and has contributed 98 book chapters. The main subjects of these publications are the pathophysiology and treatment of myoclonus and dystonia, the origin and treatment of dyskinesias in Parkinson’s disease, the pathophysiology of the ganglia, experimental models of Parkinson’s disease and the surgical treatment of Parkinson’s disease. He currently has a Hirsch index of 61. He is Chief Co-Editor of the Movement Disorders Journal since 2010. His main research interest at the moment focuses on defining the factors and characteristics that make dopaminergic neurons specially vulnerable in Parkinson’s disease, with a view to finding treatment that can delay the progress of this neurodegenerative disease.

Barry Snow, MD (New Zealand) is a neurologist based in Auckland Hospital, New Zealand. He trained in Movement Disorders at UBC, Vancouver with Donald Calne. He has lead the Movement Disorders Programme at Auckland Hospital since 1996. He is the current President of the Movement Disorders Society of Australia. His research interests include new therapies in Parkinson’s disease.

Caroline Tanner, PhD (USA) completed a residency in neurology and a fellowship in clinical neuropharmacology and movement disorders at Rush University and a doctorate in environmental health sciences at the University of California-Berkeley. Her clinical practice specializes in movement disorders, particularly Parkinson’s disease (PD), atypical parkinsonism and dystonia. Her research interests include investigations of descriptive epidemiology, environmental and genetic determinants, biomarkers, early detection, non-motor disease features and interventions for the secondary prevention, and disease modification and symptomatic treatment of movement disorders and neurodegenerative diseases. Her current research includes epidemiologic investigations of PD, multiple system atrophy, dystonia, Huntington’s disease, motor neuron disease, essential tremor and REM sleep behavior disorder in many populations, including the NAS/NRC World War II Veterans Twins Registry, the Agricultural Health Study, the Honolulu Asian Aging Study, the Alaska Native Medical Center, the legally-mandated California PD registry pilot project, the international LRRK2 PD-GEM study, the Chinese National Consortium on Neurodegenerative Diseases, the Shanghai Parkinson’s Study, the Shanghai Textile Workers Study, and the Bay Area Solvents Study.

Dr. Tanner is past co-chair of the Parkinson Study Group (PSG), and has conducted numerous clinical trials with the PSG, Neuroprotection Exploratory Trials in Parkinson’s Disease, and the Chinese Parkinson Study Group in China. Other research interests include work to facilitate collaborative research, including the NINDS Common Data Elements and the MDS Epidemiology Task Force, and work to identify PD-associated biomarkers in the Parkinson’s Progression Markers Initiative and the Longitudinal Assessment and Biomarkers Study of PD studies.

Dr. Tanner chairs the Epidemiology Task Force of the Movement Disorders Society, serves on the Executive Steering Committee of the NINDS PD Common Data Elements Committee, the Executive Council on the Sections and Subspecialties of the American Academy of Neurology and chairs several clinical trial data monitoring committees. She serves on the Scientific Advisory Boards of The Michael J. Fox Foundation and the National Spasmodic Dysphonia Association. Her honors include the Parkinson’s Disease Foundation Outstanding Woman Researcher (2004), the University of California-Berkeley Alumni Association Award for Excellence in Achievement (2008), and the American Academy of Neurology Movement Disorders Research Award (2012).

Eduardo Tolosa, MD (Spain) earned his MD degree from the University of Barcelona, Spain, and obtained his neurological training at the University of Minnesota Hospital in Minneapolis. He was visiting scientist at Brookhaven National Hospital, where he worked with George Cotzias during 1974 and 1975, and, subsequently, he joined the faculty of the Department of Neurology at the University of Minnesota. He was later appointed chief of neurology at the University Hospital in Barcelona in 1982.
Prof. Tolosa was certified as a neurologist by the American Board of Neurology and Psychiatry in 1976 and became a fellow in 1997. He is a fellow of the American Academy of Neurology, the American Neurological Association and the Royal College of Physicians, and a founding member of the Movement Disorder Society (MDS). He has been president of the MDS and president of the European Neurological Society. Prof. Tolosa is an honorary member of several neurological societies, including the British Neurological Association and the French Neurological Society.

Prof. Tolosa’s research interests have centered on movement disorders and particularly in issues related to experimental therapeutics, etiology and pathophysiology of various parkinsonisms. His team has investigated the clinical and molecular genetics of Parkinson’s disease and progressive supranuclear palsy. In the areas of experimental therapeutics, Prof. Tolosa was involved in pioneer studies defining mechanisms underlying levodopa-related motor fluctuations, both in patients and in pre-clinical models of parkinsonism. His team has been among the first in Europe to evaluate efficacy of novel surgical strategies for Parkinson’s disease such as subthalamic nucleus stimulation and its impact upon patients cognition and quality of life. In addition, during the last years, he has dedicated his investigations to the study of the asymptomatic individuals carrying PD-causative mutations in the LRRK2 gene.

Dan Weintraub, MD (USA) is Associate Professor of Psychiatry and Neurology at the University of Pennsylvania and Psychiatrist at the Parkinson’s Disease Research, Education and Clinical Center (PADRECC) at the Philadelphia Veterans Affairs Medical Center. A board-certified geriatric psychiatrist, he conducts clinical research in the psychiatric and cognitive complications of Parkinson’s disease and Alzheimer's disease, and is author of more than 100 journal articles, reviews, and book chapters. He completed a NIMH Career Development Award titled "Depression Diagnosis and Treatment in Parkinson Disease”, and has also been Principal Investigator on grants from the VA, the Institute of Aging at Penn, the Fox Foundation for Parkinson’s Research, and several industry-sponsored studies. His research has focused on the epidemiology, neural substrate, assessment and treatment of depression, psychosis, cognitive impairment and impulse control disorders in Parkinson’s disease. Dr. Weintraub previously served as an Advisor to the Cognitive Work Group of the DSM-V Task Force, was Chair of the Psychiatry Subgroup of the NINDS Common Data Elements (CDE) project, and has been a member of five Movement Disorder Society (MDS) task forces to revise and make recommendations for the assessment of cognitive and psychiatric symptoms in Parkinson’s disease. He currently is on the Editorial Board of Movement Disorders and the Journal of Parkinson’s Disease, a member of the Scientific Advisory Committee of the Lewy Body Dementia Association, on the DSMB’s for Alzheimer's Disease Cooperative Study (ADCS) and ENROLL-HD study sponsored by the Cure Huntington’s Disease Initiative, on the Executive Committee of the Parkinson Study Group (PSG), serves on the Movement Disorder Society Scales Development Committee and the Non-Motor Symptoms Workgroup, and was recently appointed Chair of the Cognitive-Behavioral Work Group for the Parkinson’s Progression Markers Initiative (PPMI) study.

Peter Fletcher, MSc, FRCP (UK) is a Consultant Physician in the Department of Old Age Medicine at Gloucestershire Hospitals NHS Foundation Trust. He specializes in Movement Disorders and shares service delivery with colleagues in Old Age Medicine, Neurology and Psychiatry as well as colleagues from nursing and the allied health professions. From a clinical base in Cheltenham, he runs clinics on four sites across a very rural County.

He is a founder member and academic director of the Parkinson's Academy and has contributed to all Masterclasses from their inception in 2002 to date. He is past Chair of the British Geriatrics Society Movement Disorders Section and is President of the Cheltenham branch of Parkinson's UK. He chairs and leads the Education group of the newly formed Parkinson's UK Excellence Network.

Dr. Fletcher is a Senior Lecturer and an Academy Medical Dean at the University of Bristol. He has an MSc in Medical Education and leads for the Medical School of interprofessional learning and personal and professional development in the curriculum. He examines third, fourth and fifth year medical students for the University of Bristol and both the Diploma of Geriatric Medicine and Membership examinations for the Royal College of Physicians of London, hosting the latter at Cheltenham.

Bastiaan Bloem, MD, PhD (Netherlands) is a consultant neurologist at the Department of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands. He received his M.D. degree (with honour) at Leiden University Medical Centre in 1993. In 1994, Professor Bloem obtained his PhD degree in Leiden, based on a thesis entitled "Postural reflexes in Parkinson's disease”. He was trained as a neurologist between 1994 and 2000, also at Leiden University Medical Centre. He received additional training as a movement disorders specialist during fellowships at ‘The Parkinson's Institute', Sunnyvale, California (with Dr. J.W. Langston), and at the Institute of Neurology, Queen Square, London (with Prof. N.P. Quinn and Prof. J.C. Rothwell). In 2002, he founded and became Medical Director of the Parkinson Centre Nijmegen (ParC), which was recognised from 2005 onwards as centre of excellence for Parkinson's disease. Together with Dr. Marten Munneke, he also developed ParkinsonNet, an innovative healthcare concept that now consists of 64 professional networks for Parkinson patients covering all of the Netherlands ( ). In September 2008, he was appointed as Professor of Neurology, with movement disorders as special area of interest. He is currently President of the International Society for Gait and Postural Research, and is on the editorial board for several national and international journals. Since 2009, he is member of the European Section Executive Committee of the Movement Disorder Society. In 2009, he also joined the board of ZonMw (The Netherlands Organisation for Health Research and Development). He currently has two main research interests: cerebral compensatory mechanisms, especially in the field of gait & balance; and healthcare innovation, aiming to develop and scientifically evaluate patient-centred collaborative care. For this latter purpose, Professor Bloem co-founded MijnZorgnet (together with Prof. Jan Kremer), a service provider that delivers web-based communities for both patients and health professionals. Professor Bloem has published over 300 publications, including more than 230 peer-reviewed international papers.

Elaine Book, SW (Canada) is the Clinic Social Worker and Center Leader for the NPF Center of Excellence, the Pacific Parkinson’s Research Centre, at the University of British Columbia in Vancouver, Canada.  Elaine earned her BSW from the University of Manitoba and her MSW from the University of British Columbia with her thesis focusing on caregiver stress.  Elaine has worked in the field of Social Work for over 25 years in a variety of community and hospital settings with an interest in the geriatric population.  Social work roles have included individual and family work as well as work as a leader of support groups. Continuing education has been ongoing and has included training in cognitive behavioral therapy, advance care planning and social work instruction as well as older adult suicide and abuse.  Elaine has also been a speaker at several PD support group meetings and neurology meetings.  Elaine continues to co-ordinate the neuro social worker blog Elaine’s dedication to improving the lives of people with Parkinson’s is greatly influenced by the determination of the patients she works with on a daily basis. Elaine may be contacted at

Terry Ellis, PT, PhD (USA) is an Assistant Professor at Boston University, College of Health & Rehabilitation Sciences in the Department of Physical Therapy & Athletic Training. Her research focuses on investigating the impact of exercise and rehabilitation on the progression of disability in individuals with Parkinson disease. She has a particular interest in identifying barriers to exercise and developing interventions to help persons with Parkinson disease overcome these barriers to engage in lifelong exercise. Dr. Ellis is the Director of the Center for Neurorehabilitation at Boston University and the Director of the American Parkinson Disease Association National Rehabilitation Resource Center housed at Boston University. Dr. Ellis has a Ph.D. in Behavioral Neurosciences from Boston University School of Medicine. She has published numerous articles and lectures internationally on topics related to rehabilitation in persons with Parkinson disease.

Joe Friedman, MD (USA) is director of the Movement Disorders Program at Butler Hospital and Professor and Chief, Division of Movement Disorders at the Warren Alpert Medical School of Brown University. He has been a member of the Parkinson Study Group since its inception, the clinical director of the RI Parkinson Information and Referral Center of the APDA since 1984. He has served on the editorial board of Movement Disorders and is currently on the editorial board of Parkinsonism and Movement Disorders. His research interests have focussed on behavioral aspects of PD and he wrote the book, Making the Connection Between Brain and Behavior: Coping with Parkinson's Disease, which discusses the many behavioral problems that PD patients and their families cope with.

Nir Giladi, MD (Israel) is a renowned leader in the field of movement disorders, an associate professor in the Sackler Faculty of Medicine at Tel Aviv University and chairman of the Department of Neurology at the Tel Aviv Sourasky Medical Center.

Prof. Giladi's research interests are in the field of gait, cognition and genetics in Parkinson's disease. In recent years Prof. Giladi, in collaboration with Prof. Orr-Urtreger, has developed and studied a unique cohort of over 900 PD patients from Ashkenazi Jewish origins, an ethnic group with unique genetic conserved substrate, using a whole genome approach as well as expression studies to identify markers in PD.

Prof. Giladi is a member of the International Parkinson and Movement Disorders Society (MDS) and is an officer (treasurer elect) since 2010. Prof. Giladi is also a member of the International Board of the Research Group of the World Health Organization on Parkinson's Disease and other Movement Disorders.

Prof. Giladi has nearly 200 papers published in peer reviewed journals and has served on the editorial boards of the Movement Disorders Journal, Parkinsonism & Related Disorders and the Journal of Neural Transmission (associate editor).

Tom Isaacs (UK) was diagnosed with Parkinson's at the young age of 27 and since then has done everything he can to raise funds, heighten awareness and find a cure for the condition which is perceived by many as a condition affecting the elderly alone.

Having completed his highly successful 1,250-mile sponsored walk in 1999, Tom left his job as Director of a London property company in April 2002 to undertake his Coastin' challenge. By April 2003, Tom had walked 4,500 miles around the British coastline, climbed the highest mountains in England, Scotland and Wales and run the Flora London Marathon, raising over £350,000. In 2004 he was runner-up in the GMTV/Daily Mirror Fundraiser of the Year Award and in 2005 he was elected Charity Personality of the Year. A year later he co-founded The Cure Parkinson’s Trust, an organization of which he is President and which has since gone on to raise over £5.5 million and has been involved in funding and facilitating ground breaking research in Parkinson’s.

Tom was a Board Member of the European Parkinson’s Disease Association from 2005 until 2010. He also represents the interests of people with Parkinson’s on DeNDRoN (the Dementias and Neurodegenerative Diseases Research Network). Tom acted as the patient representative on the Steering Committee for the World Parkinson Congress 2010 organizational committee and continues in this role for the 2013 Congress. At the 2010 Congress he made nine presentations to a variety of audiences. He is also a leading contributor to the SENSE-PARK project, which is a European funded initiative to establish a more personalized, objective measuring device for people with Parkinson’s and those who treat them.

Tom has written a book "Shake Well Before Use” about his walk and his experiences with Parkinson’s, which he conveys with passion, optimism and humor. He speaks regularly about his condition and the ability of people with Parkinson’s to inject urgency into progressing the delivery of new therapies to the clinic.

Lucie Lachance, RN (Canada) is a Clinical Nurse Specialist in Movement Disorders at the Montreal Neurological Hospital within McGill University Health Center since 2001. With the McGill Disorders Program Team, she evaluated, delivered and coordinated appropriate care for patients with complex needs and provided support and educational assistance to their families over the continuum of care required by the progressing condition associated with the Parkinson Disease and other movement disorders. One of the leader of the Movement Disorders Program at the MUHC, her activities extend well outside the MUHC as she provide guidance and disseminate best practices to nurses, allied health care professionals and others clinical partners regarding issues related to care and interdisciplinary team effectiveness in the treatment of Parkinson. She is regularly call upon as a lecturer for the Mcgill University Neuro Nursing Program and as invited speaker and organizer at various community lectures and local conferences on Parkinson targeted to the patients, their family and the health care professional. In addition, she is actively promoting an educational networking model for nurses across Canada and the Parkinson Societies at national and international conferences on Movement Disorders. She served the Parkinson Society of Canada as a board member from 2004- 2010 and since 2011. She is now the secretary of PSC. Also was a member for the Parkinson Society Quebec from 2002-2004. Lucie graduated in Nursing from Université de Sherbrooke in 1993, where she also received a M.Sc. in Clinical Science in 1996.

Anne-Louse Lafontaine, MD (Canada) has an MD from McMaster University and MSc- biostatistics and epidemiology from McGill University. She completed her residency in neurology at McGill University and went on to do a fellowship in movement disorders at the University of Calgary, Alberta. She has a strong interest in education and ethics and is currently the program director for the neurology residency training at McGill University as well as the co-chair of the research ethics board of the Montreal Neurological Hospital. Dr. Lafontaine has been very involved in the Parkinson Society Canada as a member of the board, chair of the research policy committee and currently maintains her membership on the research policy committee. She is the Director of the McGill Movement Disorder clinic.

Soania Mathur, MD (Canada) is a family physician living outside of Toronto, Ontario who had to resign her practice as a result of her Young Onset Parkinson's Disease a full twelve years after her diagnosis at age 27. Now she is a dedicated speaker, writer, educator and Parkinson's advocate. She speaks passionately about the challenges of adjusting physically and emotionally and the coping strategies available to patients. Dr. Mathur is an active speaker for the Parkinson’s Society of Canada at patient-directed conferences and also serves as a resource for education projects. She works with The Michael J. Fox foundation for Parkinson’s Research and serves on their Patient Council. She is a member of The Brian Grant Foundation Advisory Board that helps to create educational programming. She is the founder of Designing A Cure Inc. ( which was initially created to raise funds directed towards research and awareness of Parkinson's Disease and now serves as a platform to educate and inspire those living with this disease to take charge of their lives, to live well with Parkinson's. Dr. Mathur has a special interest in helping educate the youngest affected by the stress of this chronic disease. To help facilitate dialogue between children and their loved ones, she has authored two books: "My Shaky Grandpa” and "Shaky Hands, Loving Hands – A Children’s Guide To Parkinson’s Disease”. Recently, Dr. Mathur launched a new company Hippylicious ( which is dedicated to providing parents with all natural, non-toxic personal care products for their families in an effort to reduce their toxin load, a factor that she believes is significant in the development or exacerbation of many diseases. Most importantly, she is the proud mother of three beautiful daughters and married to her loving and supportive husband Arun, a Urologic suregeon.

Rebecca Miller, PhD (USA) is a Associate Research Scientist at the Yale School of Medicine Department of Psychology. Her research interests include processes of recovery from psychiatric and substance use disorders, especially innovative and community-based collaborations.

One of her focuses has been on how use of the arts, especially photography, informs a person’s personal journey and recovery, and can promote community health, especially through innovative methods such as Photovoice. With Kyle Pedersen and Lucile Bruce, she co-founded the Parachute Factory, an innovative arts collaborative between PRCH, the Community Services Network (CSN), and the Arts Council of Greater New Haven. The project’s mission is to create innovative and inclusive projects in the visual and performing arts. We opened the Parachute Factory Gallery in the spring of 2008, located within the shared offices of PRCH and the CSN at Erector Square in New Haven.

Rebecca is currently working as the Director of Peer Support and Volunteer Services at CMHC, as well as other projects related to implementing person-centered planning around the state of CT. Other interests include humor and its role in recovery and wellness, and the relationship between person and provider.

Ronald Pfeiffer, MD (USA) is Professor and Vice Chair of the Department of Neurology at the University of Tennessee Health Science Center in Memphis. He received his undergraduate and medical degrees from the University of Nebraska. Internship and neurology residency were completed at the Walter Reed Army Medical Center in Washington, D.C. His research, teaching and clinical practice focus on Parkinson's disease. He has extensive experience in clinical trials of experimental medications and a particular interest in gastrointestinal dysfunction in Parkinson's disease. Dr. Pfeiffer has been author or co-author of over 250 journal articles or book chapters and is co-editor of three books. He is Co-Editor in Chief of the journal, Parkinsonism and Related Disorders. He was chairman of the Continuing Medical Education Committee of the Movement Disorder Society from 2004 - 2010 and is currently Chair-Elect of the Movement Disorders Section of the American Academy of Neurology.

Lynn Rochester, PhD (UK) is a member of the Institute of Ageing and Health, Newcastle University and holds a BRC-funded Chair in Human Movement Science. She leads a research programme in gait and mobility disorders in age and age associated conditions within the Clinical Ageing Research Unit. Her main research interests concern gait, impact of ageing and pathology, interactions of non-motor and motor symptoms and their consequences on independent mobility, and development of interventions to improve mobility. Her studies include the development and testing of interventions to improve gait in Parkinson’s disease, application of novel technologies for assessment and intervention, such as accelerometry, and development of sensitive measures for improved diagnosis. She has published seminal translational studies defining and optimising methods to improve gait in Parkinson’s using external rhythmical stimulation which has led to changes in clinical practice worldwide following adoption into clinical guidelines.

Membership Software Powered by YourMembership  ::  Legal